Tudor Investment Corp ET AL Sells 109,061 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Tudor Investment Corp ET AL lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 35.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,011 shares of the company's stock after selling 109,061 shares during the quarter. Tudor Investment Corp ET AL owned about 0.17% of 10x Genomics worth $2,872,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in shares of 10x Genomics by 11.7% during the third quarter. Barclays PLC now owns 602,536 shares of the company's stock worth $13,605,000 after purchasing an additional 63,079 shares during the last quarter. JPMorgan Chase & Co. increased its position in 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after acquiring an additional 277,355 shares during the period. Diversified Trust Co bought a new position in shares of 10x Genomics during the fourth quarter valued at $511,000. Green Alpha Advisors LLC bought a new stake in shares of 10x Genomics in the fourth quarter worth $355,000. Finally, Assenagon Asset Management S.A. bought a new position in 10x Genomics during the 4th quarter worth $26,308,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on TXG. UBS Group cut their target price on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research report on Thursday, April 24th. Morgan Stanley dropped their price objective on 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Canaccord Genuity Group dropped their price target on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Finally, Leerink Partners downgraded 10x Genomics from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, 10x Genomics currently has an average rating of "Hold" and a consensus target price of $18.85.

Insider Activity

In other 10x Genomics news, Director Alan Mateo acquired 40,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares of the company's stock, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company's stock.

10x Genomics Price Performance

Shares of TXG traded up $0.08 during trading hours on Wednesday, hitting $8.18. The company's stock had a trading volume of 2,201,983 shares, compared to its average volume of 2,275,035. The business has a 50 day simple moving average of $9.05 and a two-hundred day simple moving average of $12.70. 10x Genomics, Inc. has a 52-week low of $6.78 and a 52-week high of $28.25. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -5.39 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Research analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.